Market Wizard
12.8K subscribers
63.8K photos
11 videos
1.16K files
21.3K links
FREE FINANCIAL EDUCATIONAL CHANNEL

Disclaimer : We are not SEBI Registered. Please consult your financial advisor before investing.

All the posts appearing in the channel are only for educational and informational purposes.

ALL RIGHTS RESERVED!!!
Download Telegram
*VST Tillers Tractors July 2021 Sales - Ok*
(Nirmal Bang Retail Research)
Total Sales came at 4397 vs YoY 3890 units (13%) and MoM 3937 units (12%)
*Eicher Motors July 2021 Sales – Below expectations*
(Nirmal Bang Retail Research)
Motorcycles (Royal Enfield) came at 44038 units vs expectation of 53817 units, YoY 40334 units (9%) and MoM 43048 units (2%)
M&HCV came at 4271 units vs expectation of 3743 units, YoY 2184 units (96%) and MoM 2438 units (75%)
*Rain Industries Ltd.* | *CMP* Rs. 261 | *M Cap* Rs. 8779 Cr | *52 W H/L* 261/89
(Nirmal Bang Retail Research)
*Result ok* Gross margin declined QoQ
Revenue from Operations came at Rs. 3643.4 Cr (21.1% QoQ, 54.3% YoY) vs QoQ Rs. 3007.7 Cr, YoY Rs. 2360.8 Cr
EBIDTA came at Rs. 647.8 Cr (11.1% QoQ, 84.2% YoY) vs QoQ Rs. 583.2 Cr, YoY Rs. 351.7 Cr
EBITDA Margin came at 17.8% vs QoQ 19.4%, YoY 14.9%
Adj. PAT came at Rs. 235.3 Cr vs QoQ Rs. 206.3 Cr, YoY Rs. 26.5 Cr
Quarter EPS is Rs. 7
Share is trading at P/E of 10.1x TTM EPS
*Home First Finance Q1FY22 Concall Update*
(Nirmal Bang Securities)

*Less than expected impact of second wave on asset quality (especially compared to larger listed peer) and robust collection trends are key positives*

*Outlook: Positive*

• Gross NPA (%) came at 1.9% vs QoQ 1.8% (Aavas at 1.1%). Co is targeting to reduce GNPA by 10 bps every qtr.
• Net NPA (%) came at 1.4% vs QoQ 1.2%.
• Restructured book is at 0.6%
• Bounce rates have improved in July to 16.1% from 18.3% in Q1. They were at 17.3% in Q4 and at ~10% levels pre-covid.
• Collection Efficiency was at 98.5% in March, it dipped to 94.0% in May and has risen to 97.6% in June, in line with Aavas.
• 1+ DPD increased to 8.9% vs QoQ 6.2% (1+ DPD for Aavas increased to 12.7% vs QoQ 6.4%)
• Disbursement runrate has reached Q4 levels in July.
• Sustainable long term spreads are in the range of 4.75-5.0% as opposed to current spread of 5.4%
• Opex/AUM should be in 2.5-3% range over next 2-3 years.
• Credit cost guidance is between 60-80bps in FY22 and should decline thereafter.
• By end of FY22, liquidity would be brought down to 500 Cr. This will support margins by 30 bps approx.
• Affordable Housing Cos’ tax rate comes to 20% due to benefits provided by Govt. Co will consider this with their new auditors once they join. (Co currently pays tax at 25.2%)

Stock is trading at 3.7x trailing P/BV
*NTPC Ltd.* | *CMP* Rs. 118 | *M Cap* Rs. 114615 Cr | *52 W H/L* 122/78
(Nirmal Bang Retail Research)
*Result is inline with expectation*
Revenue from Operations came at Rs. 26038.5 Cr (-2% QoQ, 11% YoY) vs expectation of Rs. 25259.8 Cr, QoQ Rs. 26566.9 Cr, YoY Rs. 23453.5 Cr
EBIDTA came at Rs. 7438.9 Cr (14.3% QoQ, -4% YoY) vs expectation of Rs. 7843 Cr, QoQ Rs. 6507.8 Cr, YoY Rs. 7745.1 Cr
EBITDA Margin came at 28.6% vs expectation of 31%, QoQ 24.5%, YoY 33%
Adj. PAT came at Rs. 3145.6 Cr vs expectation of Rs. 3513.6 Cr, QoQ Rs. 4771.6 Cr, YoY Rs. 2470.2 Cr
Quarter EPS is Rs. 3.2
Share is trading at P/E of 7.5x FY22E EPS
*Hero Motocorp July 2021 Sales – Below expectation*
(Nirmal Bang Retail Research)
2 Wheelers came at 454398 units vs expectation of 516333 units, YoY 520104 units (-13%) and MoM 469160 units (-3%)
*Gujarat Ambuja Exports Ltd.* | *CMP* Rs. 194 | *M Cap* Rs. 4449 Cr | *52 W H/L* 195/74
(Nirmal Bang Retail Research)
*Result improved*
Revenue from Operations came at Rs. 1025 Cr (-38.9% QoQ, 23.8% YoY) vs QoQ Rs. 1676.5 Cr, YoY Rs. 828.3 Cr
EBIDTA came at Rs. 167.7 Cr (-11.5% QoQ, 121% YoY) vs QoQ Rs. 189.5 Cr, YoY Rs. 75.9 Cr
EBITDA Margin came at 16.4% vs QoQ 11.3%, YoY 9.2%
Adj. PAT came at Rs. 113.8 Cr vs QoQ Rs. 118.4 Cr, YoY Rs. 37.3 Cr
Quarter EPS is Rs. 5
Share is trading at P/E of 10.7x TTM EPS
*Surya Roshni Ltd.* | *CMP* Rs. 529 | *M Cap* Rs. 2878 Cr | *52 W H/L* 573/112
(Nirmal Bang Retail Research)
*Result ok*
Revenue from Operations came at Rs. 1453.4 Cr (-15.6% QoQ, 64.8% YoY) vs QoQ Rs. 1721.6 Cr, YoY Rs. 881.7 Cr
EBIDTA came at Rs. 92.1 Cr (-23% QoQ, 117.3% YoY) vs QoQ Rs. 119.6 Cr, YoY Rs. 42.4 Cr
EBITDA Margin came at 6.3% vs QoQ 6.9%, YoY 4.8%
Adj. PAT came at Rs. 37.3 Cr vs QoQ Rs. 58.3 Cr, YoY Rs. 1.6 Cr
Quarter EPS is Rs. 6.9
Share is trading at P/E of 15x TTM EPS
*Unichem Laboratories Ltd.* | *CMP* Rs. 333 | *M Cap* Rs. 2345 Cr | *52 W H/L* 375/192
(Nirmal Bang Retail Research)
*Result declining*
Revenue from Operations came at Rs. 297.9 Cr (8.7% QoQ, -6.1% YoY) vs QoQ Rs. 274.1 Cr, YoY Rs. 317.3 Cr
EBIDTA came at Rs. -1.7 Cr (-108.7% QoQ, -113.7% YoY) vs QoQ Rs. 19 Cr, YoY Rs. 12.1 Cr
EBITDA Margin came at -0.6% vs QoQ 6.9%, YoY 3.8%
Adj. PAT came at Rs. -11.5 Cr vs QoQ Rs. -0.4 Cr, YoY Rs. 2.4 Cr
Quarter EPS is Rs. -1.6
Share is trading at P/E of 114.9x TTM EPS
*TGV SRACC Ltd.* | *CMP* Rs. 40 | *M Cap* Rs. 427 Cr | *52 W H/L* 41/16
(Nirmal Bang Retail Research)
*Result improved*
Revenue from Operations came at Rs. 250.7 Cr (-1.4% QoQ, 5.9% YoY) vs QoQ Rs. 254.4 Cr, YoY Rs. 236.7 Cr
EBIDTA came at Rs. 39.5 Cr (29.4% QoQ, 18% YoY) vs QoQ Rs. 30.5 Cr, YoY Rs. 33.5 Cr
EBITDA Margin came at 15.8% vs QoQ 12%, YoY 14.1%
Adj. PAT came at Rs. 9.9 Cr vs QoQ Rs. 2.6 Cr, YoY Rs. 6.2 Cr
Quarter EPS is Rs. 0.9
Share is trading at P/E of 12.8x TTM EPS
*LG Balakrishnan & Bros Ltd.* | *CMP* Rs. 464 | *M Cap* Rs. 1458 Cr | *52 W H/L* 499/200
(Nirmal Bang Retail Research)
*Result ok*
Revenue from Operations came at Rs. 392.6 Cr (-21.3% QoQ, 101.7% YoY) vs QoQ Rs. 499.1 Cr, YoY Rs. 194.6 Cr
EBIDTA came at Rs. 61.3 Cr (-30.9% QoQ, 324.6% YoY) vs QoQ Rs. 88.7 Cr, YoY Rs. 14.4 Cr
EBITDA Margin came at 15.6% vs QoQ 17.8%, YoY 7.4%
Adj. PAT came at Rs. 33 Cr vs QoQ Rs. 49.5 Cr, YoY Rs. -6.5 Cr
Quarter EPS is Rs. 10.5
Share is trading at P/E of 9.1x TTM EPS
*Bharat Heavy Electricals Ltd.* | *CMP* Rs. 59 | *M Cap* Rs. 20701 Cr | *52 W H/L* 80/27
(Nirmal Bang Retail Research)
*Result below expectation*
Revenue from Operations came at Rs. 2901.3 Cr (-59.5% QoQ, 45.7% YoY) vs expectation of Rs. 4269.5 Cr, QoQ Rs. 7171 Cr, YoY Rs. 1990.9 Cr
EBIDTA came at Rs. -474 Cr (-62.5% QoQ, -55.2% YoY) vs expectation of Rs. -343.5 Cr, QoQ Rs. -1264.3 Cr, YoY Rs. -1058.9 Cr
EBITDA Margin came at -16.3% vs expectation of -8%, QoQ -17.6%, YoY -53.2%
Adj. PAT came at Rs. -445.8 Cr vs expectation of Rs. -282.7 Cr, QoQ Rs. -1032.9 Cr, YoY Rs. -897.2 Cr
Quarter EPS is Rs. -1.3
Share is trading at P/E of 28.7x FY22E EPS
*Laurus Labs – Q1FY22 Concall Update – Nirmal Bang Sec.*
*Outlook – Positive*
_
The stock is trading at 17x FY23E on our earnings

• Lockdowns had temporary impact but the company maintained normal operations across all locations
• Focusing on having better product mix and better margins
• 3.8% R&D spend
• Filing pace to increase in FY22 across markets (Q1FY22 filings stood at 5 vs. 8 filed in FY21)
• Rs 1500-1700 cr Capex during FY22-23
• Net debt increased by Rs 170 ccr

• *_Formulations – Q1FY22 revenues of Rs 521 cr_*
o Continue to see demand in ARV segment for LMIC region and portfolio expansion in Developed markets. Traction picking up for few of in-licensed products
o Commenced marketing of in-licensed products
o 5 products filed for Developed markets (including 2 in US; total 28 ANDAs); in Canada, Laurus has 10 product approvals – launched 5 till now, intend to launch 2 in Q2 and Q3. *The company expects significant upside from these products in FY23*
o Capacity expansion update: 1) Debottlenecking Project completed during Q1 – expected to add 20% of the current capacity and 2) further FDF capacity expansion at Unit 2 (to add 4bn units) is expected to get commercialized by Q4FY22. Together these would double our FDF capacity to 10bn units


• *_APIs – Rs 549 cr revenues_*
o Oncology Segments continue to see good momentum and grew 16% YoY while the growth in Other APIs (including CVS and Diabetes portfolio) declined 43% YoY due change in the delivery schedule for certain shipments. We expect recovery from Q2
o ARV business grew at healthy 23% YoY but sequentially declined partly due to demand normalization – in line with the expectations – expected to come back on track from Q2
o Strong order book in non ARV non Onco

• *_Synthesis – Rev of Rs 195 cr_*
o There is no offs in CDMO business; it is business as usual
o Retained its significant growth momentum (+95% YoY) led by sustained new client addition and increased business from existing customers. Commercial supplies on-going for 4 products
o Capacity expansion update: have commercialized LSPL unit 1 during Q1FY22. Proposed Greenfield investment to set up a dedicated R&D center in Hyderabad (FY23) and two manufacturing units in Vizag (FY23/24) under LSPL is progressing as per the expectations


• *_Bio – Rs 14.4 cr revenues_*
o first full quarter since acquisition. On normalized basis, QoQ run-rate was stable
o Commissioned partially additional (180KL) fermentation capacity (in Food proteins) for Developed markets. *Expect full benefit of ramp up from Q2 onwards*
o Plan to acquire additional land for further expansion by creating close to 1 million liters fermentation capacity in Phase 1
o 2 fermenters came in commencement from June onwards
*Vinati Organics Ltd.* | *CMP* Rs. 1976 | *M Cap* Rs. 20310 Cr | *52 W H/L* 2132/947
(Nirmal Bang Retail Research)
*Result is below expectations*
Revenue from Operations came at Rs. 386.4 Cr (38.1% QoQ, 66.8% YoY) vs expectation of Rs. 317.4 Cr, QoQ Rs. 279.8 Cr, YoY Rs. 231.6 Cr
EBIDTA came at Rs. 101.5 Cr (2.4% QoQ, 4.5% YoY) vs expectation of Rs. 109.1 Cr, QoQ Rs. 99.1 Cr, YoY Rs. 97.2 Cr
EBITDA Margin came at 26.3% vs expectation of 34.4%, QoQ 35.4%, YoY 42%
Adj. PAT came at Rs. 80.9 Cr vs expectation of Rs. 78.5 Cr, QoQ Rs. 70.9 Cr, YoY Rs. 72.3 Cr
Quarter EPS is Rs. 7.9
Share is trading at P/E of 58.4x FY22E EPS
*PI Industries* is acquiring Ind-Swift Laboratories acquisition API and Intermediates business for Rs Rs 1530 cr (1.8x sales, 7.6x EBITDA). PI Industries has been looking opportunities to foray into Pharma CSM segment. With this acquisition it would access to API manufacturing which complements its existing Pharma R&D business. *Positive*
*Sun Pharma – Q1FY22 Concall Update – Nirmal Bang Sec.*
*Outlook – Positive*

The stock is trading at 25.5x FY23E on concences earnings

• Recorded highest ever quarterly sales
• All businesses except APIs recorded robust growth – driven by robust core business growth, low base last year and enhanced by covid portfolio
• R&D – Rs 592.6 cr
• Cost would inch up as the activity resumes however management constantly focuses in cost control measure

*Global Specialty Portfolio*
• $148mn revenues vs $81mn last year, recorded sales yoy and qoq despite loss of Absorica sales sue to entry of Absorica generics
• Illumya increased by both yoy and qoq
• Encouraged by sequential growth in Illumya and Cequia - *Expect Double digit sales in FY22*
• Specialty R&D 26% of total R&D
• Specialty R&D Pipeline – (a) Ilumya is undergoing Phase 3 clinical trials for psoriatic arthritis (b) SCD-044 undergoing Phase 2 clinical trial for atopic dermatitis and for moderate to severe plaque psoriasis (c) MM-II is also undergoing Phase 2 trial for treatment of knee pain in patients with symptomatic knee osteoarthritis (d) GLP-1 agonists is in Phase 1 trial for diabetes

*US* – 29% of consol sales in Q1
• Sales was $380mn, a growth of 35% yoy -growth was led by Specialty portfolio
• While the doctor clinics have been open in the US during the quarter the situation is yet to fully normalized
• *Expect Winlevi – an in-licensed drug, to be commercialised in Q3FY22*
• Generics
o Ex-Taro business grew by both yoy and qoq – due to better supply management and launch of new products though overall environment remains competitive
o 86 ANDAs and 13 NDAs are awaiting approvals

*India branded formulations*
• Recorded growth of 39%
• Covid and associated products accounted for 8-10% of India sales
• Chronic continued the good growth while sub chronic segment was a significant growth contributor for the quarter
• Launched 13 new products

*Other Business*
• Emerging markets - $218mn up 25% yoy, in constant currency 19% - now 17% of overall revenues
• FDs in ROW - $185mn, 35% yoy; 14% of consol revenues
• APIs – rev Rs 515 cr, down 7% yoy
World Markets

Dow - 149
Nasdaq - 106
Dax - 96
Nikkei + 462
Hangseng + 1
Sgxnifty + 102 (15877)
Brent Crude 74.83
Dow Fut + 167
Dollar Index 92.09
Stocks To Watch

Tata Motors: Plans to increase the share of electric vehicles from 2% of the portfolio to 25% in the medium to long term, said Chairman N Chandrasekaran at the AGM. The company plans to launch 10 EV models before 2025. Further, the supply issues emerging from the semiconductor crunch and pandemic will hit the company’s production volumes, sales, cash flow and margins in the near-term
said Chandrasekaran. Expect the situation to improve in the second half of the ongoing financial year. The company is also on path to wiping out its debt by FY24. In FY21 we were able to reduce debt by over Rs 7,500 crore, he added.

Coforge: Approved raising up to Rs 375 crore via share issue. It has also approved issuance of depository receipts in one or more tranches.

Torrent Power: Entered into a Securities Purchase Agreement for acquisition of 100% of the share capital and all securities of LREHL Renewables India SPV 1 from Lightsource India and Lightsource Renewable Energy. The acquisition will cost company approximately Rs 317 crore and is expected to be completed in 2 months.

Vedanta: Commenced winding-off operations at oxygen plant in Thoothukudi on July 30 to allow enough time for the defrosting process before the date indicated by the Supreme Court. As per the apex court's order on April 27, Vedanta has completed the three-month duration granted by the court to operate the oxygen plant until July 31. The company’s application for extension of the facility for a period of 6 months, is listed to be heard by the Supreme Court on August 6. The company said it is optimistic of further orders from the Supreme Court on resuming production.

Info Edge (India): Invested Rs 7 crore in 4B Networks, through its wholly owned subsidiary, to increase its shareholding in the company to 19.9% from 12.3%. The company has agreed to acquire additional 1,358 Compulsorily Convertible Preference Shares of 4B Networks.

Den Networks: The company and its wholly owned subsidiary, Futuristic Media and Entertainment, have sold their entire holding of 1.57 crore equity shares in CCN DEN Network, representing 51% of the equity share capital, to Virender Gaur and Mayank Gaur (the remaining shareholders) for Rs 8.67 crore.

Hero MotoCorp: Commenced retail sales in Mexico. The company has introduced an extensive portfolio of products, including motorcycles and a scooter, thereby catering to
the diverse segments of customers. The product portfolio will be available across the country through the retail arm of the distributor, agencies, and dealers, and will have attractive financing options, the company said.

Atul Auto: Received approval from RBI for acquisition of equity shares of Khushbu Auto Finance.

ITC: Wimco has become a wholly owned subsidiary of the company with effect from July 29, consequent to reduction of equity share capital of that company becoming effective upon receipt of necessary approvals, the company said.

Earnings: HDFC, Punjab National Bank, Emami, Castrol India, RBL Bank, Carborundum Universal, CG Power and Industrial Solutions, Orient Cement, Varun Beverages, Ajmera Realty & Infra India, Shree Renuka Sugars, Avadh Sugar & Energy, Balaji Amines, Capri Global Capital, JMC Projects (India), IFB Agro Industries, Kalyani Steels, Mangalore Chemicals & Fertilizers, Nahar Capital & Financial Services, Nahar Polyfilms, Nahar Spinning Mills, Asian Star Co
July GST collections at ₹ 1,16,393 Cr, up 33% vs same period last year.

Indirect tax revenues once again in ₹1 Lk Cr plus territory.

@FinMinIndia says this indicates the Indian economy is recovering at a fast pace and robust revenue growth would continue in coming months too.
*SGX Nifty +100 pts (15885) from last trade 15785 ,*


Nikkei +455 pts ,
Hangseng +94 pts ,
Now @6.58am .


Dow +153.60 pts ,Nsdq +15.68 pts, S&P
+18.51 pts, Bovespa -610 pts , Ftse +61 pts  , Dax +70 pts , Cac +24 pts , Crude @ $73.59 brl (-0.36), Brent @ $74.98 brl (-0.19) , Gold @ 1818.40 (+1.25), Silver @ $25.573 (+0.02), Euro @ $1.1871, JPY @ $109.64,  INR @ 74.345







*Today's Corporate Action*
*2nd  Aug Ex Date*




AARTISURF
Final Dividend - Rs. - 3.0000
ATISHAY
Final Dividend - Rs. - 0.7000
BRIGADE
Final Dividend - Rs. - 1.2000
CENTUM
Final Dividend - Rs. - 2.0000
GEPIL
Dividend - Rs. - 1.0000
ICICIGI
Final Dividend - Rs. - 4.0000
KIRLOSIND
Final Dividend - Rs. - 10.0000
LKPFIN
Dividend - Rs. - 2.0000
MAANALU
Bonus issue 1:1
MOTILALOFS
Final Dividend - Rs. - 5.0000
NESCO
Final Dividend - Rs. - 3.0000
SHK
Final Dividend - Rs. - 0.7500
STEELCAS
Dividend - Rs. - 1.3500
ULTRACEMCO
Dividend - Rs. - 37.0000







*Today's Key Results/Board Meetings*
*2-Aug-21*




AJMERA
A.G.M.;Quarterly Results
APIL
Quarterly Results
ASTAR
Quarterly Results
ATHENAGLO
Quarterly Results
AVADHSUGAR
Quarterly Results
BALAMINES
Audited Results;Quarterly Results
BSELINFRA
Quarterly Results
CARBORUNIV
Quarterly Results
CASTROLIND
Quarterly Results
CGCL
Quarterly Results
CGPOWER
Quarterly Results
CONTCHM
Quarterly Results
CORALFINAC
Quarterly Results
EARUM
Audited Results
EMAMILTD
Quarterly Results
ESCORTSFIN
General;Quarterly Results
GMPL
A.G.M.;General
GOLDENCREST
A.G.M.;Quarterly Results;General
GYANDEV
Audited Results;Quarterly Results
HBPOR
Quarterly Results
HBSTOCK
Quarterly Results
HDFC
Quarterly Results
IFBAGRO
Quarterly Results
IPRINGLTD
Quarterly Results
JMCPROJECT
General;Quarterly Results
KREONFIN
Quarterly Results
KSL
Quarterly Results
LATIMMETAL
Interim Dividend;Quarterly Results
LIKHAMI
A.G.M.;General;Quarterly Results
MANGCHEFER
Quarterly Results
NAHARCAP
Quarterly Results
NAHARPOLY
Quarterly Results
NAHARSPING
Quarterly Results
NALINLEA
Dividend;Quarterly Results
NEWLIGHT
Quarterly Results
NITTAGELA
Quarterly Results
ORIENTCEM
Quarterly Results
PNB
Quarterly Results
PRATIKSH
Quarterly Results
RAHME
Quarterly Results
RBLBANK
Quarterly Results
RENUKA
Quarterly Results
RITESHIN
General;Quarterly Results
SIMPLXMIL
Quarterly Results
SIMPLXPAP
Quarterly Results
SUCROSA
A.G.M.;Quarterly Results
SURYALAXMI
Quarterly Results
TERRAFORM
Quarterly Results
TERRAREAL
Quarterly Results
VBL
Interim Dividend;Quarterly Results
VICTORYPP
A.G.M.;General
VTMLTD
Quarterly Results




*Stock under F&O ban on NSE*
*2-Aug-21*



1SUNTV